Reducing Cancer: Survival Rates Rise After This Company Presents Milestone

G1 Therapeutics' Trilaciclib: A Promising Treatment for Extensive-Stage Small Cell Lung Cancer.

This post includes affiliate links. If you purchase anything through these affiliated links, the author/website may earn a commission.

Lung cancer is one of the most common types of cancer worldwide, with small cell lung cancer (SCLC) accounting for about 10-15% of all lung cancers. The extensive-stage small cell lung cancer (ES-SCLC), in particular, is …